** Cancer therapy maker Novocure's NVCR.O shares up 4.3% at $16.25
** NVCR says its cancer therapy, Optune Lua, to treat a type of lung cancer, has received a CE (Conformité Européenne) mark in Europe
** The CE marking certifies that a product has met EU health, safety, and environmental requirements
** CE mark approval is based on late-stage study results that showed the therapy, which uses electric fields to kill cancer cells while sparing most nearby healthy cells, also improved survival rates of patients over 8 years - NVCR
** CE mark comes after FDA's approval of Optune Lua in October 2024
** As of last close, NVCR had fallen 45.% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。